S. S. Gayle

BETi induction of mitotic catastrophe: towing the LIN9

R. Keri, Jennifer M Sahni, S. S. Gayle, 2017, Oncoscience.

Mitotic Vulnerability in Triple-Negative Breast Cancer Associated with LIN9 Is Targetable with BET Inhibitors.

Nicole A. Restrepo, P. Scacheri, G. Bebek, 2017, Cancer research.

Targeting BCL-xL improves the efficacy of bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting the death of senescent cells

R. Keri, E. Bar, Jennifer M Sahni, 2018, The Journal of Biological Chemistry.

Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance.

R. Nahta, R. O'Regan, S. S. Gayle, 2012, Anti-cancer agents in medicinal chemistry.

Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases*

J. Bradner, Jenny C. Chang, R. Keri, 2016, The Journal of Biological Chemistry.

MEK inhibition increases lapatinib sensitivity via modulation of FOXM1.

R. Nahta, R. Castellino, Meghan C. Buss, 2013, Current medicinal chemistry.

Correction: Bromodomain and extraterminal protein inhibition blocks growth of triple-negative breast cancers through the suppression of aurora kinases.

J. Bradner, Jenny C. Chang, R. Keri, 2020, Journal of Biological Chemistry.

Equity, diversity, and inclusion at the Global Alliance for Genomics and Health

J. Meléndez-Zajgla, S. Chandrasekharan, B. Llamas, 2023, Cell Genomics.